# Rock425

Source: https://onco.cc/drugs/rock425/  
OnCo record `rock425` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rock425 is an experimental immunotoxin from Rock Immune that carries a disabled diphtheria toxin to malignant T cells. It is being developed for cutaneous T-cell lymphoma and has not yet been tested in people.

## Summary

Rock425 (CCR4-IL2 IT) is Rock Immune's lead candidate: a genetically engineered protein containing an anti-human CCR4 scFv and human IL-2 fused to truncated diphtheria toxin, expressed in the company's diphtheria toxin-resistant Pichia pastoris system. Rock Immune reports preclinical efficacy in a mouse model of human cutaneous T-cell lymphoma. No registered trial was found.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: CCR4-IL2 IT; CCR4-IL2 bispecific immunotoxin
- Tags: pipeline
- Modality: Recombinant immunotoxin (bispecific fusion protein)
- Mechanism: An anti-CCR4 single-chain antibody fragment and human IL-2 fused to a truncated diphtheria toxin, so that the toxin is carried into cells bearing CCR4 or the IL-2 receptor, as described by Rock Immune.

## Sources

- Rock Immune: https://rockimmune.com/

## Connected records

- targets: [CCR4](https://onco.cc/targets/ccr4/)
- companies: [Rock Immune](https://onco.cc/companies/rock-immune/)

---
JSON: https://onco.cc/api/v1/entities/rock425.json